Diagnosis of neuroendocrine tumours by retrospective image fusion: is there a benefit?

What Was Tested

This clinical trial looks at Somatostatin.

This study evaluated the use of image fusion in the preoperative staging of neuroendocrine tumors (NET) of the pancreas and the gastrointestinal tract (GIT).

Thirty-eight patients suffering from a metastasized NET with location of the primary in the pancreas ( n=15) or the GIT ( n=23) were examined by somatostatin receptor scintigraphy (SRS) and computed tomography (CT).

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

A total of 87 foci were assigned to anatomical regions (e.g. gut, pancreas, liver, lymph node or others) by two independent observers in both SRS and SRS/CT fusion images.

What Was Measured

This study evaluated the use of image fusion in the preoperative staging of neuroendocrine tumors (NET) of the pancreas and the gastrointestinal tract (GIT).

Thirty-eight patients suffering from a metastasized NET with location of the primary in the pancreas ( n=15) or the GIT ( n=23) were examined by somatostatin receptor scintigraphy (SRS) and computed tomography (CT).

The subject headings attached to it are Gastrointestinal Neoplasms, Image Enhancement, Neuroendocrine Tumors, Pancreatic Neoplasms, Radiography, Radionuclide Imaging and Radiopharmaceuticals.

What This Means in Plain Language

This is a clinical trial of Somatostatin.

The publication is from 2004 (European journal of nuclear medicine and molecular imaging), a journal based in Germany.

More context: the related Somatostatin library page, all human trials.